The combination of a BRAF V600E inhibitor plus a downstream MEK inhibitor avoids paradoxical activation of the MAPK pathway in normal tissues, reducing the risk of skin tumors while enhancing pathway inhibition within BRAF mutant tumors [12, 13]. This evidence concerns the gene BRAF and skin neoplasm.